Deborah M. Stephens

5.3k total citations
142 papers, 1.7k citations indexed

About

Deborah M. Stephens is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Deborah M. Stephens has authored 142 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Genetics, 78 papers in Pathology and Forensic Medicine and 40 papers in Oncology. Recurrent topics in Deborah M. Stephens's work include Chronic Lymphocytic Leukemia Research (110 papers), Lymphoma Diagnosis and Treatment (77 papers) and Advanced Breast Cancer Therapies (19 papers). Deborah M. Stephens is often cited by papers focused on Chronic Lymphocytic Leukemia Research (110 papers), Lymphoma Diagnosis and Treatment (77 papers) and Advanced Breast Cancer Therapies (19 papers). Deborah M. Stephens collaborates with scholars based in United States, United Kingdom and Italy. Deborah M. Stephens's co-authors include John C. Byrd, Jennifer A. Woyach, William G. Wierda, Sonali M. Smith, Farrukh T. Awan, John M. Pagel, Jennifer R. Brown, Priti Patel, Peter Hillmen and Richard R. Furman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Deborah M. Stephens

125 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Deborah M. Stephens United States 22 1.1k 1.0k 630 354 342 142 1.7k
Manfred Hensel Germany 21 903 0.8× 988 0.9× 490 0.8× 310 0.9× 517 1.5× 68 1.6k
Pau Abrisqueta Spain 22 1.0k 1.0× 873 0.8× 636 1.0× 174 0.5× 421 1.2× 124 1.8k
Celeste Bello United States 13 808 0.7× 640 0.6× 544 0.9× 250 0.7× 247 0.7× 63 1.3k
Krimo Bouabdallah France 22 1.4k 1.3× 798 0.8× 1.1k 1.8× 391 1.1× 452 1.3× 119 2.1k
Charles Herbaux France 23 1.2k 1.1× 1.1k 1.0× 675 1.1× 460 1.3× 591 1.7× 111 1.9k
Tycel Phillips United States 22 956 0.9× 554 0.5× 899 1.4× 278 0.8× 367 1.1× 149 1.6k
Christian H. Geisler Denmark 25 1.8k 1.6× 1.2k 1.2× 1.1k 1.7× 305 0.9× 512 1.5× 52 2.4k
Patricia Aoun United States 22 1.4k 1.3× 635 0.6× 885 1.4× 184 0.5× 327 1.0× 48 1.8k
Christopher Pocock United Kingdom 23 1.2k 1.1× 1.1k 1.1× 809 1.3× 810 2.3× 244 0.7× 64 2.1k
Andrew Haynes United Kingdom 15 1.0k 1.0× 655 0.6× 516 0.8× 168 0.5× 370 1.1× 36 1.3k

Countries citing papers authored by Deborah M. Stephens

Since Specialization
Citations

This map shows the geographic impact of Deborah M. Stephens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah M. Stephens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah M. Stephens more than expected).

Fields of papers citing papers by Deborah M. Stephens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah M. Stephens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah M. Stephens. The network helps show where Deborah M. Stephens may publish in the future.

Co-authorship network of co-authors of Deborah M. Stephens

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah M. Stephens. A scholar is included among the top collaborators of Deborah M. Stephens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah M. Stephens. Deborah M. Stephens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huang, Xiaomeng, Yi Qiao, Philip J. Moos, et al.. (2025). Long-read single-cell RNA sequencing enables the study of cancer subclone-specific genotypes and phenotypes in chronic lymphocytic leukemia. Genome Research. 35(4). 686–697.
2.
Viviani, Simonetta, Chiara Pavoni, Sally F. Barrington, et al.. (2025). Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials. Blood Cancer Journal. 15(1). 165–165.
3.
4.
高橋, 義行, Xiaomeng Huang, Philip J. Moos, et al.. (2024). A Bayesian framework to study tumor subclone–specific expression by combining bulk DNA and single-cell RNA sequencing data. Genome Research. 34(1). 94–105. 2 indexed citations
5.
Shadman, Mazyar, Sudeep Karve, Bruno Émond, et al.. (2024). Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia & lymphoma. 66(1). 44–53. 3 indexed citations
6.
Stephens, Deborah M., Chris Stewart, Catherine C. Coombs, et al.. (2024). Feasibility of Discontinuation of Bruton's Tyrosine Kinase Inhibitors in Patients with Chronic Lymphocytic Leukemia: A Patient Survey. Blood. 144(Supplement 1). 7743–7743.
7.
Karmali, Reem, Jeremy S. Abramson, Deborah M. Stephens, et al.. (2023). Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma. Blood Advances. 7(23). 7361–7368. 3 indexed citations
8.
Shah, Harsh, Lindsey Fitzgerald, Randa Tao, et al.. (2023). Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy. Clinical Lymphoma Myeloma & Leukemia. 24(2). 94–104.e6. 1 indexed citations
9.
Woyach, Jennifer A., Deborah M. Stephens, Ian W. Flinn, et al.. (2023). First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma. Cancer Discovery. 14(1). 66–75. 29 indexed citations
10.
11.
Goyal, Gaurav, Amy J. Davidoff, Scott F. Huntington, et al.. (2023). The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Network Open. 6(6). e2316642–e2316642. 5 indexed citations
12.
13.
Stephens, Deborah M., Ying Huang, Amy S. Ruppert, et al.. (2022). Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Clinical Cancer Research. 28(15). 3242–3247. 20 indexed citations
14.
Stephens, Deborah M., Hongli Li, Louis S. Constine, et al.. (2022). Extranodal presentation in limited-stage diffuse large Bcell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001. Haematologica. 107(11). 2732–2736.
15.
Brown, Jennifer R., John C. Byrd, Paolo Ghia, et al.. (2021). Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 107(6). 1335–1346. 26 indexed citations
16.
Persky, Daniel O., Hongli Li, Deborah M. Stephens, et al.. (2020). Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. Journal of Clinical Oncology. 38(26). 3003–3011. 64 indexed citations
17.
Awan, Farrukh T., Anna Schuh, Jennifer R. Brown, et al.. (2019). Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Advances. 3(9). 1553–1562. 144 indexed citations
18.
Stephens, Deborah M., Hongli Li, Heiko Schöder, et al.. (2019). Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood. 134(15). 1238–1246. 71 indexed citations
19.
Stephens, Deborah M. & John Sweetenham. (2015). Clinical Controversies of Double-Hit Lymphoma. 11(4). 4 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manfred Hensel Breakdown of academic impact, for papers by Pau Abrisqueta Breakdown of academic impact, for papers by Celeste Bello Breakdown of academic impact, for papers by Krimo Bouabdallah Breakdown of academic impact, for papers by Charles Herbaux Breakdown of academic impact, for papers by Tycel Phillips Breakdown of academic impact, for papers by Christian H. Geisler Breakdown of academic impact, for papers by Patricia Aoun Breakdown of academic impact, for papers by Christopher Pocock Breakdown of academic impact, for papers by Andrew Haynes
Rankless by CCL
2026